

13TH DRESDEN SYMPOSIUM ON AUTOANTIBODIES

Dresden, September 27-30, 2017

CRTD – 01307 Dresden, Fetscherstraße 105

**4th International Consensus on ANA Pattern (ICAP) Workshop
3rd International Autoantibody Standardization (IAS) Workshop**

Dresden, September 26, 2017

BiInnovationsZentrum – 01307 Dresden, Tatzberg 47



Final Programme

The congress venue 2017: Centre for Regenerative Therapies (CRTD) in 01 307 Dresden, Fetscherstrasse 105
(picture: Clemens A. Schulze Lohoff)



WELCOME

Dear Colleagues,

On behalf of the Organizing Committee it is a great pleasure to welcome you to our 13th Dresden Symposium on Autoantibodies. The symposium is organized by the Institute of Immunology of the Medical Faculty of the Technical University Dresden in cooperation with the Association for the Advancement of Immunodiagnosics (www.gfid-ev.de) and the Section Immunodiagnosics of the German Society for Clinical Chemistry and Laboratory Medicine (www.dgkl.de). The meeting intends to bring together clinicians of different disciplines, immunologists and basic researchers for discussion of the various aspects of the induction, pathogenetic role and clinical relevance of autoantibodies as well as methodical aspects of autoantibody testing. The current symposium is entitled „Immunodeficiency, Infection and Autoimmune Diseases“. An attractive scientific program has been developed together with the Co-chairs and the International Advisory Board as well as the Advisory Board of the Association for the Advancement of Immunodiagnosics which represents also the DGKL Section of Immunodiagnosics. We would like to express our thanks to the members of the International Advisory Board and to the active contributors who will present their latest achievements as well as to the many sponsors who enabled this symposium. The organizers of the symposium are deeply grateful to the Center of Regenerative Medicine Dresden (CRTD) and in particular to the Director of the CRTD, Professor Ezio Bonifacio, for placing at our disposal this wonderful congress venue.

Autoimmune diseases are complex immune-mediated diseases that involve both endogenous and environmental factors in their etiopathogenesis. During the 13th Dresden Symposium on Autoantibodies, special aspects of the autoimmune pathogenesis like the role of infections, vaccination, primary immunodeficiencies, the complement and functional autoantibodies as well as novel aspects regarding the pathogenesis, diagnosis and prediction of rheumatoid arthritis will be presented and discussed. Further main topics deal with the current state and recent developments of the serological diagnostics of systemic and organ specific autoimmune diseases. Subjects that are addressed include diagnostic strategies, methodical aspects of the analysis of anti-cellular, anti-neutrophil cytoplasmic and anti-phospholipid antibodies, the role of anti-DFS70 antibodies, and the description of novel clinically or pathophysiologically relevant autoantibodies.

As the 13th Dresden Symposium on Autoantibodies focuses again on methodical aspects of autoantibody testing, we are delighted to host the 4th International Consensus on ANA Pattern (ICAP) Workshop as a continuation of the 3rd ICAP Workshop held in October 2016 at the IWAA in Kyoto and the 3rd International Autoantibody Standardization (IAS) Workshop as a continuation of the 2nd IAS Workshop held at our last Dresden Symposium on Autoantibodies in September 2015.

We expect that our 13th Dresden Symposium on Autoantibodies as well as the ICAP and IAS workshops will stimulate a broad debate on how the new achievements from the bench work could help to improve diagnostics and therapy of autoimmune diseases. We hope that you will enjoy the scientific programme and your stay in Dresden.

Karsten Conrad
On behalf of the Organizing Committee

TUESDAY
SEPTEMBER 26

PROGRAMME

4th International Consensus on ANA Pattern (ICAP) Workshop

09.00-11.00

4th ICAP WORKSHOP PART I

Co-Chaired by Marvin Fritzler and Minoru Satoh

09.00-09.30

Overall update on ICAP

Edward K.L. Chan

- www.ANAPatterns.org website, users and membership
- Funding issues, relationship to International Union of Immunological Societies (IUIS)/ Autoantibody Standardization Committee (ASC)
- Babel project (translation into multi languages)
- Image submission and voting process
- Educational Program planning (Luis Andrade)

09.30-11.00

Clinical relevance of AC (Anti-Cell) patterns

Jan Damoiseaux and Carlos Alberto von Mühlen

- Introduction, established guideline (Jan Damoiseaux)
- AC-1 to AC-14 nuclear patterns (Jan Damoiseaux)
- AC-15 to AC-23 cytoplasmic patterns (Carlos A. von Mühlen)

11.00-11.30

COFFEE BREAK

11.30-13.30

4th ICAP WORKSHOP PART II

Co-Chaired by Carlos Alberto von Mühlen
and Jan Damoiseaux

11.30-11.50

Clinical relevance of AC patterns (continue)

- AC-24 to AC-28 discussion - selected especially those needing comments (Manfred Herold)

11.50-12.20

Establishment of two new AC patterns: AC-0 and AC-29

Manfred Herold and Werner Klotz

- Rationale for having these examples/patterns
- AC-0 negative examples (Manfred Herold)
- AC-29 Topo I-like description (Werner Klotz)
- AC-29 – clinical relevance (Manfred Herold)

12.20-12.50

Limits in defining AC patterns in the daily laboratory practice

Luis E.C. Andrade

12.50-13.00

Does double staining help with assigning AC-21?

Edward K.L. Chan

13.00-13.30

A re-visit/discussion in ANA reporting
(moderated by Jan Damoiseaux)

- Cytoplasmic positive is reported as ANA + (Carlos A. von Mühlen)
- Cytoplasmic positive is not reported as ANA + (Michael Grünwald)
- Anti-cellular antibodies =ANA? (Luis Andrade)

13.30-15.00

LUNCH BREAK

3rd International Autoantibody Standardization (IAS) Workshop

Co-Chairs: Pier Luigi Meroni and Joanna Sheldon

3rd IAS WORKSHOP PART I

Introduction

Pier Luigi Meroni (Milan, Italy)

Report from each initiative on ongoing standardization processes

- Australasian: Tiffany Hughes (Bedford Park, Australia)
- ASC/IUIS: Edward Chan (Gainesville, USA)
- EASI: Jan Damoiseaux (Maastricht, The Netherlands)
- ECFSG: Johan Rönnelid (Uppsala, Sweden)
- IFCC: Joanna Sheldon (London, UK) and Ingrid Zegers (Bruxelles, Belgium)
- NIBSC/WHO: Bernhard Fox and Lucy Studholme (Potters Bar/UK)

COFFEE BREAK

3rd IAS WORKSHOP PART II

Why standardization is so critical in autoantibody testing?

Luis E.C. Andrade (São Paulo, Brazil)

WRAP-UP SESSION: What are the main problems/needs in autoantibody testing and the possible solutions right now?

Plenary discussion chaired by Edward K.L. Chan, Yehuda Shoenfeld, Johan Rönnelid, Joanna Sheldon

- The reference materials prepared (or going to be prepared) by the different groups display different requirements/characteristics: there is the need to specify this issue for each material available. The goal should be a list of the available ref materials with all their characteristics to be circulated among the people involved in the field.
- For each reference material, we should include also: its performance in the different techniques/platforms; titer evaluation, possible cross-reactivity with other antigens; stability as well.
- Which kind of reference material is still missing?
- Logistic for distribution of standards (central production but not necessarily centralized storage/distribution).
- Homogenous way for validation.
- IAS quality seal? Or at least a certificate from the IAS members that tested the ref materials?
- The possibility to convince Diagnostic Companies to calibrate their Units and kits according to our standards. The harmonization of the available ref materials should help in facilitating the issue of the financial support from the Companies.
- The need for well-defined disease and control cohorts.
- The need for a Coordinating Committee?
- The visibility of our initiatives in the web sites (already working).
- Establishment of a Website as the communication tool with the scientific and business community (or links among the existing web sites).
- Charge for shipment of standards.
- Where and when till the 4th IAS meeting takes place (Next IWAA in Berlin? Next ICA in Lisbon?)

15.00-16.30

15.00-15.10

15.10-16.30

16.30-16.45

16.45-18.45

16.45-17.00

17.00-18.45

WEDNESDAY
SEPTEMBER 27

08.00-22.00

Registration

10.30-11.00

Welcome and Introduction

11.00-12.30

PRIMARY IMMUNODEFICIENCIES AND AUTOIMMUNITY

Co-Chairs: Karsten Conrad (Dresden, Germany)
Elena Csernok (Kirchheim, Germany)

11.00-11.30

Autoimmune manifestations in primary immunodeficiencies
Frédéric Rieux-Laucat (Paris, France)

11.30-11.55

Pathogenesis of autoimmunity in common variable
immunodeficiency
Ulrich Salzer (Freiburg, Germany)

11.55-12.10

Autoimmune diseases in primary immune deficiency patients:
a broad range in a referral immunology center
*Ceyda Tunakan Dalgıç, Fatma Ömür Ardeniz, Aytül Zerrin Sin
(Izmir, Turkey)*

12.10-12.30

What can we learn from primary immunodeficiencies for the risk
stratification of biologics used for treatment of autoimmune
diseases
Jan Damoiseaux (Maastricht, The Netherlands)

12.30-14.00

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

Poster P1-P37

14.00-15.30

INFECTIONS AND AUTOIMMUNITY

Co-Chairs: Dimitrios Bogdanos (Larissa, Greece)
Carlos Casiano (Loma Linda, USA)

14.00-14.30

Microbial infections, neutrophil extracellular traps and their
connection to autoimmunity
Marco Radic (Memphis, USA)

14.30-14.50

Unnoticed microbial mimics of autoimmune rheumatic
diseases-specific autoantigens
Dimitrios Bogdanos (Larissa, Greece)

14.50-15.10

Circulating cell-free nucleic acids in rheumatoid arthritis: clues
for the involvement of microbes in the pathophysiology?
Ger Pruijn (Nijmegen, The Netherlands)

15.10-15.30

Alpha Enolase, a common autoantigen in infection,
autoimmunity, and cancer
Carlos Casiano (Loma Linda, USA)

15.30-16.00

COFFEE BREAK

WEDNESDAY
SEPTEMBER 27

**AUTOIMMUNE DIAGNOSTICS USING ULTRAFAST IFT
MICROSCOPY COMBINED WITH ULTIMATE MONOSPECIFIC
DETECTION PROCEDURES**

(sponsored by EUROIMMUN Medizinische Labordiagnostika AG)

Co-Chairs: Winfried Stöcker (Lübeck, Germany)
Jan Damoiseaux (Maastricht, The Netherlands)

Efficient IFA workflows from sample identification to final report of autoantibody analyses 16.00-16.15

Kai Fechner (Lübeck, Germany)

Performance analysis of automated evaluation of anti-nuclear antibody indirect immunofluorescent tests in a routine setting 16.15-16.40

Jan Damoiseaux (Maastricht, The Netherlands)

ANA testing: The renaissance of indirect immunofluorescence assay 16.40-17.05

Vincent Ricchiuti (Dublin, USA)

Ultrafast EUROPattern: A new era in automatic IFA microscopy 17.05-17.15

Panagiotis Grypiotis (Lübeck, Germany)

Laboratory diagnostics of autoantibodies in autoimmune myopathies 17.15-17.30

Wolfgang Meyer (Lübeck, Germany)

Clinical implications of anti-cN-1A testing in inclusion body myositis 17.30-17.45

Anke Rietveld (Nijmegen, The Netherlands)

Prevalence and consequence of autoantibodies in a large systemic sclerosis cohort 17.45-18.00

Ruben Smeets (Nijmegen, The Netherlands)

GET TOGETHER - POSTER AND EXHIBITION VIEWING 18.00

THURSDAY
SEPTEMBER 28

08.30-10.30

NOVEL ASPECTS OF AUTOANTIBODIES IN AUTOIMMUNE LIVER DISEASE, NECROTIZING MYOPATHIES AND RHEUMATOID ARTHRITIS

(sponsored by Inova Diagnostics, Inc.)

Co-Chairs: Michael Mahler (San Diego, USA)
Leendert Trouw (Leiden, The Netherlands)

08.30-08.45

Autoantibodies in autoimmune liver disease
Dimitrios Bogdanos (Larissa, Greece)

08.45-09.00

Novel biomarkers for primary biliary cholangitis (PBC) - Anti-hexokinase 1 and anti-kelch-like 12 antibodies
Gary Norman (San Diego, USA)

09.00-09.15

Performance evaluation of QUANTA Flash LKM-1 and Mit-3
Roger Albesa (San Diego, USA)

09.15-09.40

Background and recent update of autoimmune myositis
Zoe Betteridge (Bath, UK)

09.40-10.00

Recent updates on anti-HMGCR antibodies and performance evaluation of QUANTA Flash HMGCR
Silvia Casas (Barcelona, Spain)

10.00-10.15

Added value by combining autoantibody results in Rheumatoid Arthritis
Leendert Trouw (Leiden, The Netherlands)

10.15-10.30

Utility of anti-PAD3 antibodies in management of Rheumatoid Arthritis
Laura Martinez-Prat (San Diego, USA)

10.30-11.00

COFFEE BREAK - POSTER AND EXHIBITION VIEWING

11.00-12.30

TRENDS IN AUTOANTIBODY TESTING

Co-Chairs: Nicola Bizzaro (Tolmezzo, Italy)
Joanna Sheldon (London, UK)

11.00-11.30

Trends in autoantibody testing: The imperative of autoimmune disease prevention
Marvin Fritzler (Calgary, Canada)

11.30-11.50

Summary of the 3rd International Autoantibody Standardization (IAS) Workshop
Joanna Sheldon (London, UK)

11.50-12.10

ANCA harmonization of test interpretation
Xavier Bossuyt (Leuven, Belgium)

12.10-12.20

Multiparametric models as an aid in the diagnosis of rheumatoid arthritis
Michael Mahler, Chelsea Bentow, Roger Albesa, Laura Cesana, Laura Martinez-Prat, Pascale Roux-Lombard, Michael Nissen, Celine Lamacchia, Cem Gabay (San Diego, USA)

| | |
|---|--------------------|
| A phage display screen for novel theranostic autoantibodies in rheumatoid arthritis <i>Patrick Vandormael, Dana Quaden, Patrick Verschueren, Veerle Somers (Hasselt, Belgium)</i> | 12.20-12.30 |
| LUNCH BREAK – POSTER AND EXHIBITION VIEWING | 12.30-14.00 |
| Poster P38-P65 Guided poster presentation of the Candidates for the Dresden Prize Chair: Ulrich Sack (Leipzig, Germany) | |
| EASI FORUM MEETING (EASI members only) | 12.30-14.00 |
| Conference room of the BioInnovationsZentrum in the neighbouring building | |
| STANDARDIZATION/HARMONIZATION OF ANA TESTING | 14.00-15.30 |
| Co-Chairs: Luis E.C. Andrade (São Paulo, Brazil) Manfred Herold (Innsbruck, Austria) | |
| Novel aspects and future directions in ANA testing <i>Michael Mahler (San Diego, USA)</i> | 14.00-14.30 |
| Proposed ICAP refinements - how to move forward <i>Edward K.L. Chan (Gainesville, USA)</i> | 14.30-14.45 |
| The robustness of indirect immunofluorescence (IIF) patterns in the anti-cellular antibody test on HEp-2 cells (HEp-2-IIF) <i>Luis E.C. Andrade (São Paulo, Brazil)</i> | 14.45-15.00 |
| The association of solid-phase assays to immunofluorescence for ANA screening increases the clinical specificity of diagnostic tests in patients with autoimmune rheumatic diseases. Results of a large collaborative study <i>Nicola Bizzaro (Tolmezzo, Italy)</i> | 15.00-15.15 |
| Adapting ANA pattern nomenclature to the ICAP recommendations: first experience from proficiency testing and routine diagnosis <i>Martin Blüthner (Karlsruhe, Germany)</i> | 15.15-15.30 |
| COFFEE BREAK | 15.30-16.00 |

THURSDAY
SEPTEMBER 28

16.00-18.00

PATHOGENESIS AND PREDICTION OF RHEUMATOID ARTHRITIS

Co-Chairs: Günter Steiner (Vienna, Austria)
Johan Rönnelid (Uppsala, Sweden)

- 16.00-16.30 Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis
Anca I. Catrina (Stockholm, Sweden)
- 16.30-16.55 Autoantibodies against modified proteins in RA
Leendert Trouw (Leiden, The Netherlands)
- 16.55-17.20 Population based screening for ACPA: A step in the pathway to the prevention of rheumatoid arthritis?
Michael Mahler (San Diego, USA)
- 17.20-17.45 Can autoantibodies be used as tools for prediction of therapeutic responses in patients with rheumatoid arthritis?
Günter Steiner (Vienna, Austria)
- 17.45-18.00 Evaluation of the 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis in a secondary care hospital with 7 different anti-cyclic citrullinated peptide antibody and 6 different rheumatoid factor assays
Lieve Van Hoovels, Julie Jacobs, Bert Vander Cruyssen, Stefanie Van den Bremt, Patrick Verschueren, Xavier Bossuyt (Aalst, Belgium)
- 18.00-19.30** **EASI Austria & Germany Meeting** (for EASI members only)
Conference room of the BioInnovationsZentrum in the neighbouring building

**EMERGING DIAGNOSTIC TECHNOLOGIES AND NOVEL
AUTOANTIGENIC TARGETS IN THE SEROLOGY OF
AUTOIMMUNE DISEASES**

(sponsored by MEDIPAN GmbH and Generic Assays GmbH)

Co-Chairs: Dirk Roggenbuck (Dahlewitz, Germany)
Dimitrios Bogdanos (Larissa, Greece)

Identification of chitinase 3 like-1-protein as a neutrophil autoantigenic target in inflammatory bowel diseases and autoimmune liver disorders

Claudia Deutschmann (Senftenberg, Germany)

08.30-08.50

A novel 3rd generation TSH-receptor antibody (TRab) enzyme-linked immunosorbent assay based on a murine monoclonal TSH receptor-binding inhibitory antibody

Johannes Roggenbuck (Dresden, Germany)

08.50-09.10

Mucosal autoimmunity to cell-bound GP2 isoforms 1 and 4 is a sensitive marker in severe primary sclerosing cholangitis

Mandy Sowa (Senftenberg, Germany)

09.10-09.30

Simultaneous detection of celiac-disease specific IgA antibodies and total IgA by CytoBead assay – comprehensive celiac serology

Kai Grossmann (Dahlewitz, Germany)

09.30-09.50

Analysis of antiganglioside antibodies by a line immunoassay in patients with chronic inflammatory demyelinating polyneuropathies

Juliane Klehmet (Berlin, Germany)

09.50-10.10

Antinuclear antibody and nuclease serum activity as biomarkers of response to infliximab in rheumatoid arthritis

Marharyta Volkava (Minsk, Belarus)

10.10-10.30

COFFEE BREAK - POSTER AND EXHIBITION VIEWING

10.10-10.30

FUNCTIONAL AND PATHOGENIC AUTOANTIBODIES

11.00-12.45

Co-Chairs: Ger J.M. Pruijn (Nijmegen, The Netherlands)
Fritz Boege (Düsseldorf, Germany)

Functional autoimmunity to G protein-coupled receptors

Gabriela Riemekasten (Lübeck, Germany)

11.00-11.20

The pathogenic effects of autoantibodies against beta1-adrenergic receptors in chronic heart failure

Roland Jahns (Würzburg, Germany)

11.20-11.40

Signal and Noise - diagnostics of autoantibodies against beta 1-adrenergic receptors in clinical settings

Fritz Boege (Düsseldorf, Germany)

11.40-12.00

Functionally active antibodies against type II collagen drive an acute onset rheumatoid arthritis phenotype

Johan Rönnelid (Uppsala, Sweden)

12.00-12.15

FRIDAY
SEPTEMBER 29

- 12.15-12.30 Treatment strategies for functional autoantibody disease
Ingolf Schimke (Berlin, Germany)
- 12.30-14.00 LUNCH BREAK – POSTER AND EXHIBITION VIEWING
- Poster P66-P100**
- 14.00-15.30 EUROPEAN AUTOIMMUNITY STANDARDIZATION INITIATIVE (EASI) SYMPOSIUM**
- Co-Chairs: Yehuda Shoenfeld (Tel-Hashomer, Israel)
Nina Olschowka (Freiburg, Germany)
- 14.00-14.10 What is EASI?
Nina Olschowka (Freiburg, Germany)
- 14.10-14.30 ANA / ENA questionnaire and EASI recommendations
Jan Damoiseaux (Maastricht, The Netherlands)
- 14.30-14.50 The new international consensus on ANCA testing
Xavier Bossuyt (Leuven, Belgium)
- 14.50 -15.05 Support of laboratories in certification
Nicola Bizzaro (Tolmezzo, Italy)
- 15.05-15.20 Some major projects of the local EASI groups
Manfred Herold (Innsbruck, Austria)
- 15.20-15.30 Questionnaire on the use of ANA, RF and ACPA in clinical practice: results from the EASI groups in Austria and France
Nicole Fabien, Lucile Musset, Manfred Herold, Jan Damoiseaux, Maria José Sousa (Lisbon, Portugal)
- 15.30-16.00 COFFEE BREAK
- 16.00-17.30 ETIOPATHOGENESIS OF SYSTEMIC AUTOIMMUNE DISEASES**
- Co-Chairs: Edward K.L. Chan (Gainesville, USA)
Pier Luigi Meroni (Milan, Italy)
- 16.00-16.30 Human Papilloma virus (HPV) and its vaccine as a novel cause of SLE
Yehuda Shoenfeld (Tel Hashomer, Israel)
- 16.30-16.50 Innate immunity in antiphospholipid syndrome
Pier Luigi Meroni (Milan, Italy)
- 16.50-17.10 Cytomegalovirus as trigger of autoimmune rheumatic diseases: the case of systemic sclerosis
Dimitrios Bogdanos (Larissa, Greece)
- 17.10-17.30 Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis
Gabriela Riemekasten (Lübeck, Germany)
- 17.45 Departure to Dresden Palace (Zwinger) Social Dinner**

AUTOANTIBODIES IN SYTEMIC AUTOIMMUNE DISEASES

08.30-10.30

Co-Chairs: Minoru Satoh (Kitakyushu, Japan)
Carlos Alberto von Mühlen (Porto Alegre, Brazil)

Pathophysiological and genetic studies in ANCA-associated vasculitis point to a new disease classification based on autoantibodies

08.30-08.50

Elena Csernok (Kirchheim, Germany)

Neutrophil extracellular traps are a substrate for the detection and discrimination of anti-neutrophil cytoplasmic antibodies

08.50-09.00

Thorsten Krieger, Rachita Panda, Luke Hopf, Thomas Renné, Friedrich Haag, Nadja Röber, Karsten Conrad, Elena Csernok, Tobias A. Fuchs (Hamburg, Germany)

Interference of perinuclear anti-neutrophil cytoplasmic antibody (P-ANCA) detection by antinuclear antibody specificities

09.00-09.10

Carolina Auza, Michael Mahler, May Choi, Erika Aron, Marvin Fritzler (Calgary, Canada)

Update on autoantibodies in necrotizing myopathies, with special regard to anti-HMGCR

09.10-09.35

Carlos Alberto von Mühlen (Porto Alegre, Brazil)

Incidence of myositis-specific autoantibodies profiles and specificities in sera referred to New Zealand medical laboratories

09.35-09.50

John O'Donnell, Paula Keating, Mark van Voorthuizen, John Liu, Ignatius Chua, Andrew Soepnel, Elysia Gumbley, Myfanwy Spellerberg (Christchurch, New Zealand)

Sjögren's syndrome – Do we need to identify novel autoantibodies?

09.50-10.05

Manfred Herold (Innsbruck, Austria)

Epitope mapping of anti-Ro52 antibody responses in patients with autoimmune rheumatic diseases reveals differential epitope recognition

10.05-10.20

Athanasios Gkoutzourelas, Christos Liaskos, Tomas Scheper, Wolfgang Meyer, Dimitrios P. Bogdanos, Lazaros I. Sakkas (Larissa, Greece)

Anti-β2-glycoprotein I autoantibody expression as a potential biomarker for strokes in patients with anti-phospholipid syndrome

10.20-10.30

Husham Bayazed and Zainalabideen A. Abdullah (Zakho, Iraque)

COFFEE BREAK - POSTER AND EXHIBITION VIEWING

10.30-11.00

SATURDAY,
SEPTEMBER 30

11.00-12.30

NOVEL AUTOANTIBODIES AND METHODOLOGICAL ASPECTS

Co-Chairs: Marvin J. Fritzler (Calgary, Canada)
Minoru Satoh (Kitakyushu, Japan)

11.00-11.15

Characterization of cryptic antinuclear autoantibody target antigens

Zitao Zeng, Ramona Miske, Madeleine Scharf, Yvonne Denno, Christian Probst, Winfried Stöcker, Lars Komorowski (Lübeck, Germany)

11.15-11.30

Autoimmunity as a putative stratifying factor of the clinical phenotype in Crohn's disease

Dirk Roggenbuck, Dirk Reinhold, Daniel Baumgart, Peter Schierack, Claudia Deutschmann, Karsten Conrad, Martin W. Laass (Senftenberg, Germany)

11.30-11.45

Autoantigenic rods/rings assembly correlates with T cell activation

S. John Calise and Edward K.L. Chan (Gainesville, USA)

11.45-12.00

Antibody profiling identifies novel antigenic targets in spinal cord injury patients

Ilse Palmers, Elke Ydens, Eric Put, Bart Depreitere, Helma Bongers-Janssen, Peter Pickkers, Sven Hendrix, Veerle Somers (Diepenbeek, Belgium)

12.00-12.15

Searching for autoantibodies in "seronegative" axial spondylo-arthritis

Dana Quaden, Patrick Vandormael, Liesbeth De Winter, Piet Geusens, Veerle Somers (Diepenbeek, Belgium)

12.15-12.30

Novel minor nuclear autoantigens in type 1 diabetes

Denise Müller, Tanja Teliëps, Anne Eugster, Manja Jolink, Anette Gabirele Ziegler, Ezio Bonifacio (Munich, Germany)

12.30-13.30

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

13.30-15.00

ORGAN SPECIFIC AUTOIMMUNE DISEASES AND TUMORS

Co-Chairs: Karsten Conrad (Dresden, Germany)
Xavier Bossuyt (Leuven, Belgium)

13.30-14.00

Prevalences of 39 anti-neural autoantibodies in 40.000 diagnosed samples

Winfried Stöcker (Lübeck, Germany)

14.00-14.20

Autoantibodies in interstitial lung disease and lung cancer

Minoru Satoh (Kitakyushu, Japan)

14.20-14.30

Helicobacter pylori in multiple sclerosis: an ideal model of microbiota-triggered autoimmunity?

Dimitrios Bogdanos (Larissa, Greece)

SATURDAY,
SEPTEMBER 30

Immunomics profiling on high density protein-arrays elucidates autoantibody increase one year before clinical diagnosis of ulcerative colitis

14.30-14.40

Andreas Weinhaeusel, G. Beikircher, S. Schönthaler, R. Soldo, P. Hettegger, C. Noehammer, K. Vierlinger, R. Kulovics, M. Siebeck, R. Gropp (Vienna, Austria)

Anti-C1q antibodies in patients with multiple sclerosis and other various neurological diseases

14.40-14.50

Christos Liaskos, Stamatina Rentouli, Georgios Efthymiou, Athanasios Gkoutzourelas, Zisis Tsouris, Gary L. Norman, Zisis Mamouris, Efthimios Dardiotis, Lazaros I. Sakkas, Georgios Hadjigeorgiou, Dimitrios P. Bogdanos (Larissa, Greece)

Differentiation of autoantibody response against Zinc transporter 8 in autoimmune diabetes

14.50-15.00

Michael Schlosser, Kathrin Wilhelm, Uwe Walschus, Kirsten Kesselring, Vito Lampasona, Ilona Rjasanowski, Wolfgang Kerner (Greifswald, Germany)

Dresden Prize Award Ceremony & Conclusion

15.00-16.00

FAREWELL COFFEE BREAK

16.00-17.00

WEDNESDAY,
SEPTEMBER 27
(12.30) until
SATURDAY,
SEPTEMBER 30
(13.30)

POSTER EXHIBITION
(second and third floor of the congress venue)

P1 Ultrafast EUOPattern: A new era in automatic IFA microscopy. *Jörn Voigt, Markus Morrin, Panagiotis Grypiotis, Tilman Johannes Sumpf, Martin Hagen-Eggert, Moritz Pavlik (Lübeck, Germany)*

P2 Efficient IFA workflows from sample identification to final report of autoantibody analyses. *Kai Fechner (Lübeck, Germany)*

P3 Laboratory diagnostics of autoantibodies in autoimmune myopathies. *Wolfgang Meyer (Lübeck, Germany)*

P4 Performance analysis of automated evaluation of anti-nuclear antibody indirect immunofluorescent tests in a routine setting. *Jan Damoiseaux, Kathleen Mallet, Joyce van Beers, Melanie Hahn, Christopher Krause, Wymke Hormann, Kai Fechner (Maasricht, The Netherlands)*

P5 Automated processing and evaluation of anti-nuclear antibody indirect immunofluorescence testing. *Vincent Ricchiuti (Dublin, OH, USA)*

P6 Is the prevalence of anti-DFS70 antibodies increasing? Experience from large blood donor and longitudinal studies. *Roger Albesa, Ulrich J. Sachs, Maria Infantino, Mariangela Manfredi, Maurizio Benucci, Yvonne Baus, Luis Andrade, Kieran Morris, Alice Friedenberg, Xavier Bossuyt, Silvia Casas, Michael Mahler (San Diego, CA, USA)*

P7 Fecal Calprotectin: evaluation of a novel chemiluminescence method. *Mirko Ginnaio, Giulia Previtali, Rudi Ravasio, Tiziana Benedetti, Giovanna Lazzari, Ferdinanda Noris, Caterina Maestroni, Francesca Nembrini, Michela Seghezzi, Valentina Moioli, Michele Tang, Maria Grazia Alessio (Bergamo, Italy)*

P8 iVYCHECK GIP URINE: a useful support to monitor the glutenfree diet (GDF) in celiac patients? *Mirko Ginnaio, Giulia Previtali, Rudi Ravasio, Tiziana Benedetti, Giovanna Lazzari, Ferdinanda Noris, Caterina Maestroni, Francesca Nembrini, Michela Seghezzi, Valentina Moioli, Michele Tang, Maria Grazia Alessio (Bergamo, Italy)*

P9 New opportunity for the diagnosis of autoimmune liver diseases. *Mirko Ginnaio, Giulia Previtali, Rudi Ravasio, Tiziana Benedetti, Giovanna Lazzari, Ferdinanda Noris, Caterina Maestroni, Francesca Nembrini, Michela Seghezzi, Valentina Moioli, Michele Tang, Maria Grazia Alessio (Bergamo, Italy)*

P10 Anti- β 2-glycoprotein I autoantibody expression as a potential biomarker for strokes in patients with anti-phospholipid syndrome. *Husham Bayazed, Zainalabideen A. Abdullah (Zakho, Kurdistan, Iraq)*

P11 Autoantibody spectrum in a large consecutive cohort of patients with epileptic seizures & suspicious for limbic encephalitis. *Julia C. Kuehn, Susanne Schoch McGovern, Rainer Surges, Elke Hattingen, Christian E. Elger, Albert J. Becker (Bonn, Germany)*

P12 The contribution of routinely monitoring of ANCA titers in patients with granulomatosis with polyangiitis differs between assay platforms. *Stien Vandendriessche, Filip De Keyser, Lieve Van Hoovels, Carolien Bonroy (Ghent, Belgium)*

P13 The detection of myositis-specific antibodies by lineblot in relation to the clinical diagnosis and the indirect immunofluorescence pattern. *Yves Piette, Maxime De Sloovere, Stien Vandendriessche, Matthieu Versaevel, Joke Dehoorne, Jan De Bleecker, Liesbet Van Praet, An-Sofie Vander Mijnsbrugge, Peggy Jacques, Filip De Keyser, Vanessa Smith, Carolien Bonroy (Ghent, Belgium)*

P14 A fully automated platform capable of processing, scanning and analyzing IFA substrates. *John Breneman, Sarah Paul, Jeri Seiki, Roger Walker (Hercules, CA, USA)*

P15 Rare association of anti-NMDAR antibodies and herpes virus type 7 in woman with encephalitis. *Ángela Carrasco Sayalero, José Ignacio Fernández Velasco, Amalia Tejada Velarde, Adriano Jiménez-Scrig, Israel Gañán Nieto (Madrid, Spain)*

P16 Routine use of an expanded EIA ANCA specificity profile. *John B. Carter, Sara Carter (West Columbia, SC, USA)*

P17 Optimization of antinuclear antibody screening using a computer-aided immunofluorescence microscopy system. *Alex Chin (Calgary, Canada)*

P18 What is the frequency of neurological antibodies? *Sylvie Coito (Belvaux, Luxembourg)*

P19 Celiac disease and scleroderma: a case report. *Maria José Sousa, Margarida Albuquerque, Rita Ribeiro, M. Favila Menezes, José Germano de Sousa, Germano de Sousa (Lisbon, Portugal)*

P20 Performance comparison between EliATM Symphony and EliA SymphonyS in a cohort of 633 clinically defined samples. *Stephan Giesler, Elke Kicherer, Melanie Müller, Katharina Weis, Peter Höpfl (Freiburg, Germany)*

P21 Documentation of cytoplasm abs on laboratory reports and results of further testing ordered by physicians. *Michael L. Grünwald, Irene Kolbe, Gerhard Schloz (Augsburg, Germany)*

P22 Frequency of myositis specific autoantibodies in unselected serum samples with creatine kinase activity > 500 U/l. *Michael L. Grünwald, Irene Kolbe, Sabine Würkner, Bianca Teegen (Augsburg, Germany)*

WEDNESDAY,
SEPTEMBER 27
(12.30) until
SATURDAY,
SEPTEMBER 30
(13.30)

P23 ANA on HEp-2 cells presuming DFS70 pattern – reflex test on anti-DFS70 or more? *Manfred Herold, Werner Klotz, Daniel Filchtinski, Thomas Horn (Innsbruck, Austria)*

P24 Autoantibodies in Sjögren's syndrome. *Manfred Herold, Werner Klotz (Innsbruck, Austria)*

P25 Comparison of two systems for the detection of anti-cardiolipin and anti- β_2 -glycoprotein antibodies in an Italian cohort with thrombotic predisposition. *Maria Infantino, Valentina Grossi, Maurizio Benucci, Francesca Li Gobbi, Francesca Bandinelli, Arianna Damiani, Caterina Bodio, Orietta Maria Borghi, Michael Mahler, Mary Ann Aure, Chelsea Bentow, Mariangela Manfredi (Florence, Italy)*

P26 QuantiFERON-TB Gold Plus test: memory and current T-cell-mediated immune responses to Mycobacterium tuberculosis infection. *Darina Kozakova, Elizabeth Zanova, Monika Polanova, I. Rybar (Piestany, Slovakia)*

P27 Anti-phospholipase A2 receptor antibody testing in primary membranous nephropathy. *Ana Kozmar, Mario Laganovic, Nada Tomic Sremec (Zagreb, Croatia)*

P28 The diagnostic relevance of anti-DFS70 among the patients with suspicion of systemic autoimmune rheumatic disease in North Estonia Medical Centre, Estonia. *Maiga Mägi, Marge Kütt (Tallinn, Estonia)*

P29 The clinical associations of autoantibodies in liver diseases. *Liisa Kuhi (Tallinn, Estonia)*

P30 Tryptophan-Kynurenine profile and autoantibodies in pediatric autoimmune hepatitis. *Marcin Osiecki, Marek Woynarowski, Małgorzata Wozniak, Bożena Cukrowska, Aldona Wierzbicka, Maria Goliszek, Piotr Socha, Wojciech Janczyk, Dilek Dayanakli, Dietmar Fuchs, Sabine Kramp, Kai Fechner, Thomas Scheper, Michael Mahler, Chelsea Bentow, Dieter Abendroth, Simon D. Lytton (Munich, Germany)*

P31 Autoantibodies associated with liver disease in systemic sclerosis patients. *Boyang Zheng, Andrea Seaman, Marvin Fritzier, Martial Koenig, Marychel Tiongson, Gary L. Norman, Michael Mahler (San Diego, CA, USA)*

P32 New markers for celiac disease and glutensensitivity: anti-neo-epitope human and microbial transglutaminases. *Torsten Matthias, Patricia Jeremias, Sandra Neidhofer, Aaron Lerner (Wendelsheim, Germany)*

P33 MMP-3 serum levels correlate to therapy response in RA patients. *Sandra Reuter, Patricia Jeremias, Silvia Brunner, Andreas Schwarting, Torsten Matthias (Wendelsheim, Germany)*

P34 Performance comparison of the HELMED® blot module and HELIA® using AESKUBLOTS® ANA-17 Pro. *Carsten Jung, Karola Krausse, Christian Klein, Torsten Matthias (Wendelsheim, Germany)*

P35 Serological performance of AESKU.SEVEN-UP compared to DiaSorin and EUROIMMUN ELISA Borrelia kits. *Jens Blecken, Stefan Platzgummer, Kai Prager, Alexandra Joos, Aaron Lerner, Torsten Matthias (Wendelsheim, Germany)*

P36 Standardisation of measurements of autoantibodies for ANCA-associated small vessel vasculitis. *Evanthia Monogioudi, Gustavo Martos, Dana Hutu, Pier Luigi Meroni, Joanna Sheldon, Heinz Schimmel, Ingrid Zeger (Geel, Belgium)*

P37 The value of anti-dsDNA antibody tests in the monitoring systemic Lupus Erythematosus disease activity. *Thierry Dervieux, Tyler O'Malley, John Conklin, Claudia Ibarra, Chelsea Bentow, Mary Ann Aure, Eckart Mummert, Michael Mahler (San Diego, CA, USA)*

P38 Combination of novel and classical liver markers demonstrate utility in diagnosing primary biliary cholangitis. *Albert Parés, Anna Reig, Silvia Ruiz-Gaspa, Mila Garcia, Gary L. Norman, Mary Ann Aure, Susan Encabo, Chelsea Bentow, Michael Mahler, Maria Antonia Romera, Odette Viñas (San Diego, CA, USA)*
CANDIDATE FOR THE DRESDEN PRIZE

P39 Evaluation of two specific biomarkers for the diagnosis of primary biliary cholangitis in a Spanish cohort. *Mila Garcia, Gary L Norman, Roger Albesa, Silvia Ruiz-Gaspà, Anna Reig, Mary Ann Aure, Jay Milo, Susan Encabo, Chelsea Bentow, Michael Mahler, Odette Viñas, Albert Parés (San Diego, CA, USA)*
CANDIDATE FOR THE DRESDEN PRIZE

P40 Comparison of an immunofluorescence method with a solid phase chemiluminescence immunoassay for the detection and quantification of anti-HMGCR antibodies. *Carolina Auza, Laura Martinez, Roger Albesa, Michael Mahler (San Diego, CA, USA)*
CANDIDATE FOR THE DRESDEN PRIZE

P41 Accurate detection and titration of ANCA on NOVA View® automated fluorescence microscope. *Carolina Auza, Jonathan De Anda, Erika Arón, Marlene Gonzalez, Chelsea Bentow, Michael Mahler (San Diego, CA, USA)*
CANDIDATE FOR THE DRESDEN PRIZE

P42 Autoantigenic rods/rings assembly correlates with T cell activation. *S. John Calise, Edward K.L. Chan (Gainesville, FL, USA)*
CANDIDATE FOR THE DRESDEN PRIZE

WEDNESDAY,
SEPTEMBER 27
(12.30) until
SATURDAY,
SEPTEMBER 30
(13.30)

P43 Antinuclear antibodies (ANA) patterns in paraneoplastic cerebellar degeneration during the time course of disease and treatment protocols – A case report. *Amira Cerimagic, Nejra Džananovic (Sarajevo, Bosnia and Herzegovina)*

CANDIDATE FOR THE DRESDEN PRIZE

P44 Interference of perinuclear anti-neutrophil cytoplasmic antibody (P-ANCA) detection by antinuclear antibody specificities. *Carolina Auza, Michael Mahler, May Choi, Erika Aron, Marvin Fritzier (Calgary, AB, Canada)*

CANDIDATE FOR THE DRESDEN PRIZE

P45 Coincidence of DFS70 antibodies and relevant ANAs in patients at the University Clinics of Cologne and Bonn. *Ramona Dolscheid-Pommerich, Thomas Streichert, Birgit Stoffel-Wagner, Wibke Johannes (Berlin, Germany)*

CANDIDATE FOR THE DRESDEN PRIZE

P46 Antibody responses against human cytomegalovirus antigens in patients with systemic sclerosis. *Georgios Efthymiou, Christos Liaskos, Emmanouela Marou, Theodora Simopoulou, Thomas Scheper, Wolfgang Meyer, Dimitrios P. Bogdanos, Lazaros I. Sakkas (Larissa, Greece)*

CANDIDATE FOR THE DRESDEN PRIZE

P47 Anti-C1q antibodies in patients with multiple sclerosis and other various neurological diseases. *Christos Liaskos, Stamatina Rentouli, Georgios Efthymiou, Athanasios Gkoutzourelas, Zisis Tsouris, Gary L. Norman, Zisis Mamouris, Efthimios Dardiotis, Lazaros I. Sakkas, Georgios Hadjigeorgiou, Dimitrios P. Bogdanos (Larissa, Greece)*

CANDIDATE FOR THE DRESDEN PRIZE

P48 Functional impairment of IL-10 producing B cells is not a universal characteristic of patients with relapsing-remitting multiple sclerosis. *Georgios Efthymiou, Efthymiou Dardiotis, Athanasios Mavropoulos, Christos Liaskos, Zisis Tsouris, Lazaros I. Sakkas, Georgios Hadjigeorgiou, Dimitrios P. Bogdanos (Larissa, Greece)*

CANDIDATE FOR THE DRESDEN PRIZE

P49 Epitope mapping of anti-Ro52 antibody responses in patients with autoimmune rheumatic diseases reveals differential epitope recognition. *Athanasios Gkoutzourelas, Christos Liaskos, Tomas Scheper, Wolfgang Meyer, Dimitrios P. Bogdanos, Lazaros I. Sakkas (Larissa, Greece)*

CANDIDATE FOR THE DRESDEN PRIZE

P50 Antibodies against Ro52/TRIM21 positively associate with B regulatory cells in patients with systemic sclerosis. *Athanasios Mavropoulos, Athanasios Gkoutzourelas, Christos Liaskos, Dimitrios P. Bogdanos, Lazaros I. Sakkas (Larissa, Greece)*

CANDIDATE FOR THE DRESDEN PRIZE

P51 Is the presence of an associated autoimmune disease sufficient to distinguish primary from secondary Sjogren syndrome? A bi-centric retrospective descriptive study. *Melek Kechida, C. Manzo, M. Natale, R. Klii, S. Hammami, I. Khochtali, R. Cioffi (Monastir, Tunisia)*

CANDIDATE FOR THE DRESDEN PRIZE

P52 Hashimoto thyroiditis associated to Sjogren syndrome: a local autoimmune epithelitis associated to a systemic one? *Melek Kechida, C. Manzo, M. Natale, R. Klii, S. Hammami, I. Khochtali, R. Cioffi (Monastir, Tunisia)*

CANDIDATE FOR THE DRESDEN PRIZE

P53 Glycan structure of myelin oligodendrocyte glycoprotein (MOG) and its impact on autoantibody recognition. *Iris Marti-Fernandez, Paul Hensbergen, Melania Spadaro, Agnes Hipgrave-Ederveen, Lisa Ann Gerdes, Reinhard Hohlfeld, Tania Kämpfel, Inge Huitinga, Dieter Jenne, Stefanie Hauck, Manfred Wuhrer, Edgar Meinl (Munich, Germany)*

CANDIDATE FOR THE DRESDEN PRIZE

P54 Multiparametric models as an aid in the diagnosis of rheumatoid arthritis. *Michael Mahler, Chelsea Bentow, Roger Albesa, Laura Cesana, Laura Martinez-Prat, Pascale Roux-Lombard, Michael Nissen, Celine Lamacchia, Cem Gabay (San Diego, CA, USA)*

CANDIDATE FOR THE DRESDEN PRIZE

P55 Antibody profiling identifies novel antigenic targets in spinal cord injury patients. *Ilse Palmers, Elke Ydens, Eric Put, Bart Depreitere, Helma Bongers-Janssen, Peter Pickkers, Sven Hendrix, Veerle Somers (Diepenbeek, Belgium)*

CANDIDATE FOR THE DRESDEN PRIZE

P56 Patients with psoriasis are presented with antinuclear antibody positivity prior to immunosuppressive treatment. *Eleni Patrikiou, Christos Liaskos, Athanasios Gkoutzourelas, Aggeliki Roussaki-Schulze, Efterpi Zafiriou, Lazaros I. Sakkas, Dimitrios P. Bogdanos (Larissa, Greece)*

CANDIDATE FOR THE DRESDEN PRIZE

P57 Screening for antibody reactivity in axial spondyloarthritis using a cDNA phage display library. *Dana Quaden, Patrick Vandormael, Liesbeth De Winter, Piet Geusens, Veerle Somers (Diepenbeek, Belgium)*

CANDIDATE FOR THE DRESDEN PRIZE

P58 Autoimmune diseases in primary immune deficiency patients: a broad range in a referral immunology center. *Ceyda Tunakan Dalgıç, Fatma Ömür Ardeniz, Aytül Zerrin Sin (Izmir, Turkey)*

CANDIDATE FOR THE DRESDEN PRIZE

WEDNESDAY,
SEPTEMBER 27
(12.30) until
SATURDAY,
SEPTEMBER 30
(13.30)

P59 Comparison of different methods using in detection of anti-dsDNA antibodies. *Ceyda Tunakan Dalgic, Hüseyin Süner, Selda Sen, Reyhan Akar, Sibel Ayaz, Atif Özbek, Aytul Zerrin Sin (Izmir, Turkey)*

CANDIDATE FOR THE DRESDEN PRIZE

P60 Analytical and clinical comparison of two fully automated immunoassay systems for the detection of autoantibodies to extractable nuclear antigens. *Pieter van der Pol, Liesbeth E. Bakker-Jonges, Jac H.S.A.M. Kuijpers, Herbert Hooijkaas, Marco W.J. Schreurs (Delft, The Netherlands)*

CANDIDATE FOR THE DRESDEN PRIZE

P61 Characterization of cryptic antinuclear autoantibody target antigen. *Zitao Zeng, Ramona Miske, Madeleine Scharf, Yvonne Denno, Christian Probst, Winfried Stöcker, Lars Komorowski (Lübeck, Germany)*

CANDIDATE FOR THE DRESDEN PRIZE

P62 Novel minor nuclear autoantigens in Type 1 Diabetes. *Denise Müller, Tanja Teliëps, Anne Eugster, Manja Jolink, Anette Gabriele Ziegler, Ezio Bonifacio (Dresden, Germany)*

CANDIDATE FOR THE DRESDEN PRIZE

P63 Questionnaire on the use of ANA, RF and ACPA in clinical practice: results from the EASI groups in Austria and France. *Nicole Fabien, Lucile Musset, Manfred Herold, Jan Damoiseaux, Maria José de Sousa (Lisbon, Portugal)*

CANDIDATE FOR THE DRESDEN PRIZE

P64 Autoantibodies against glycoprotein 2 isoforms in pediatric inflammatory bowel disease. *Lydia Noß, Nadja Röber, Alexander Goihl, Dirk Reinhold, Josefine Jahn, Jan de Laffolie, Johannes Wolf, Dirk Roggenbuck, Karsten Conrad, Martin Walter Laass (Dresden, Germany)*

CANDIDATE FOR THE DRESDEN PRIZE

P65 ANTI-RO52/TRIM21: Unanswered questions. *May Y. Choi, Michael Mahler, Ann E. Clarke, Marvin J. Fritzler (Calgary, AB, Canada)*

CANDIDATE FOR THE DRESDEN PRIZE

P66 Myositis autoantibodies. *Zoe Betteridge (Bath, UK)*

P67 Meta-analysis of autoantibodies to domain 1 of beta 2 glycoprotein I as biomarker for risk management in antiphospholipid syndrome. *Eckart Mummert, Gary L. Norman, Rohan Willis, Anisur Rahman, Pier Luigi Meroni, Munther A. Khamashta, Michael Mahler (San Diego, CA, USA)*

P68 Evaluation of adalimumab and etanercept-induced immunogenicity in a cohort of Hungarian patients with immune-mediated inflammatory diseases. *Eszter Nagy, Emese Kiss, Zsuzsa Schmidt, Judit Korda, Krisztina Sevcic, Ilonka Orb-n, Rita Rasonyi, Gyula Poór (Budapest, Hungary)*

P69 Similar geographic prevalence of anti-hexokinase and anti-kelch like peptide antibodies in patients with primary biliary cholangitis - A large international multi-center study. *Gary L. Norman, Zakera Shums, Silvia Ruiz-Gaspà, Maria Antonia Romera, Odette Viñas, Mila Garcia, Anna Reig, Susan Encabo, Jay Milo, Chelsea Bentow, Michael Mahler, Ewa Wunsch, Piotr Milkiewicz, Mark G. Swain, Andrew Mason, Laura M. Stinton, Natalia Baeza, Marvin J. Fritzler, Albert Parés (San Diego, CA, USA)*

P70 INOVA Autoimmunity solution: workflow analysis of the impact on laboratory standardization and productivity. *Stefan Platzgummer, Elisabeth Raffener, Michele Giacomi (Merano, Italy)*

P71 Prevalence of anti-THSD7A autoantibodies in Italian anti-PLA2R-negative idiopathic membranous nephropathy (IMN). *Antonella Radice, Barbara Trezzi, Federico Umberto Emilio Guglielmo Pieruzzi, Gianmarco Ghiggeri, Pietro Napodano, Tiziana Stellato, Sabine Lederer, Rachele Brugnano, Vincenzo Cantaluppi, Raffaella Cravero, Marco D'Amico, Marco Farina, Maria Enrica Giovenzana, Francesco Londrino, Fabio Malberti, Gianpaola Pesce, Federica Ravera, Davide Rolla, Giuseppe Rombolà, Domenico Santoro, Angela Volpi, Gabriella Moroni, Francesca Pregnotato, Giuseppe Ortisi, Renato Alberto Sinico (Milan, Italy)*

P72 Comparison of the EliaTM anti-TSH-R assay with the BrahmsTM TRAK human radioimmunoassay in the detection of thyroid-stimulating hormone receptor antibodies. *Christoph Robier, Gerald Eibinger, Birgit Schr[^]ttner, Eva Petnehazy (Graz, Austria)*

P73 Autoantibody profiling in aqueous humour of patients with uveitis. *Josianne C. ten Berge, Aniki Rothova, Joost van Rosmalen, Marco W.J. Schreurs (Rotterdam, The Netherlands)*

P74 Serum autoantibody profiling of patients with paraneoplastic and non-paraneoplastic autoimmune retinopathy. *Josianne C. ten Berge, Joost van Rosmalen, Jacolien Vermeer, Cecilia Hellström, Cecilia Lindskog, Peter Nilsson, Ulrika Qundos, Aniki Rothova, Marco W.J. Schreurs (Rotterdam, The Netherlands)*

P75 The diagnostic performance of the novel EliA SymphonyS test. *Roseri J.A.C. Roelofsen-de Beer, JosÈ Huybers, Jac H.S.A.M. Kuijpers, Marco W.J. Schreurs (Rotterdam, The Netherlands)*

WEDNESDAY,
SEPTEMBER 27
(12.30) until
SATURDAY,
SEPTEMBER 30
(13.30)

P76 High density peptide microarrays with posttranslational modifications for the multiplexed analysis of immune profiles in rheumatoid arthritis and other autoimmune diseases. *Renate Sekul (Heidelberg, Germany)*

P77 Comparison and evaluation of different methodologies and tests for detection of antimitochondrial antibodies. *Aytul Zerrin Sin, Ceyda Tunakan Dalgic, Reyhan Akar, Sibel Ayaz, Atif Ozbey, Selda Sen (Izmir, Turkey)*

P78 High level of IL-36 in psoriatic arthritis PsA patients hospitalized at the Rheumatology Clinic of Medical University in Wroclaw, Poland. *Renata Sokolik, Lucyna Korman, Piotr Wiland (Wroclaw, Poland)*

P79 Anti-drug antibodies (ADA): assay performance in patients treated for inflammatory bowel and rheumatic disease with biodrugs, adalimumab and infliximab. *John O'Donnell, John Liu, Paula Keating, Barry Hock, Myfanwy Spellerberg, Murray Barclay, Lisa Stamp (Christchurch, New Zealand)*

P80 Comparison of anti-DFS70 reactivity with the Line immunoassay and ELISA and concordance with dense fine speckled fluorescence pattern on HEp-2 cells. *Andrea Tešija Kuna, Ines Vukasovic, Milena Njegovan, Lovorka Derek, Nada Vrkic (Zagreb, Croatia)*

P81 Evaluation of an immunodot for the detection of antiphospholipid antibodies in view of the lack of a reference standard: application of latent class analysis. *Markus Thaler, Andreas Bietenbeck, Udo Steigerwald, Thomas Büttner, Peter Bauer, Edelgard Lindhoff-Last, Dirk Roggenbuck, Peter B. Lupp (Munich, Germany)*

P82 Comparison of new multi-line immunodot assay and ELISA for the detection of antiphospholipid antibodies. *Olga Tkachenko, Sergey Lapin, Alexandra Mazing, Sergey Selkov, Sergey Chepanov, Dirk Roggenbuck (St. Peterburg, Russia)*

P83 Analytical and diagnostic evaluation of three serum calprotectin assays. *Lieve Van Hoovels, Mathieu Cauchie, Stefanie Van den Bremt, Muriel Stubbe, Xavier Bossuyt, Bert Vander Cruyssen (Aalst, Belgium)*

P84 Technical performance of 7 anti-cyclic citrullinated peptide antibody and 6 rheumatoid factor assays in the diagnosis of rheumatoid arthritis. *Lieve Van Hoovels, Julie Jacobs, Bert Vander Cruyssen, Stefanie Van den Bremt, Patrick Verschueren, Xavier Bossuyt (Aalst, Belgium)*

P85 Optimization of a cost-effective diagnostic ANA algorithm. *Mathieu Cauchie, Bert Vander Cruyssen, Stefanie Van den Bremt, Muriel Stubbe, Xavier Bossuyt, Lieve Van Hoovels (Aalst, Belgium)*

P86 Inclusion of anti-DFS70 Ab identification in the diagnostic algorithm of ANA: one year of experience. *Mathieu Cauchie, Muriel Stubbe, Stefanie Van den Bremt, Bert van der Cruyssen, Xavier Bossuyt, Lieve Van Hooveles* (Aalst, Belgium)

P87 The isotype distribution of antibodies against novel UH-RA peptides in rheumatoid arthritis. *Liesbeth De Winter, Patrick Vandormael, Piet Geusens, Jan Lenaerts, Johan Vanhoof, Piet Stinissen, Veerle Somers* (Diepenbeek, Belgium)

P88 Detection of GAD65 in human serum: A potential marker of beta cell destruction in autoimmune diabetes? *Uwe Walschus, Katja Herchenröder, Kirsten Kesselring, Heidrun Kenk, Michael Schlosser* (Greifswald, Germany)

P89 Multicentre MOG antibody detection. *Patrick Waters, Lars Komorowski, Fabienne Brilot, Sean J. Pittock, Christian Probst, Monika Probst, Markus Reindl* (Oxford, UK)

P90 The plasmatic lipoprotein-associated phospholipase A2 concentration and activity are possible new markers for thrombotic risk in patients with anti- β 2-glycoprotein I antibodies? *Martina Fabris, Adriana Cifù, Cinzia Pistis, Rossana Domenis, Francesco Curcio, Elio Tonutti* (Udine, Italy)

P91 Improving the ANA test by CRISPR/Cas9-induced PSIP1 knockout in HEp-2 cells. *Lysann Sauer, Stefan Rüdiger, Juliane Scholz, Madeleine Ruhe, Nadja Röber, Peter Schierack, Karsten Conrad, Dirk Roggenbuck, Christian Schröder* (Senftenberg, Germany)

P92 Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. *Yovana Pacheco, Julian Barahona-Correa, Diana M. Monsalve, Jenny Acosta-Ampudia, Manuel Rojas, Yhojan Rodríguez, Juliana Saavedra, Mónica Rodríguez-Jiménez, Rubén Mantilla, Carolina Ramírez-Santana, Nicolás Molano-González, Juan-Manuel Anaya* (Bogotá, Colombia)

P93 Discordance between two autoantibodies detection methods: Conventional ELISA vs. IMTEC-ANA-LIA Maxx. *Yovana Pacheco, Diana M. Monsalve, Yeny Acosta-Ampudia, Juan-Manuel Anaya* (Bogotá, Colombia)

P94 A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against TIF1 γ . *Susann Meisterfeld, Nadja Röber, Karsten Conrad, Stefan Beisert, Martin Aringer, Claudia Günther* (Dresden, Germany)

P95 An ANA screening assay containing multiple antigens increases the sensitivity and specificity of ANA testing by indirect immunofluorescence. *Thomas Karonitsch, Hans Kiener, Thomas Horn, Günter Steiner* (Vienna, Austria)

WEDNESDAY,
SEPTEMBER 27
(12.30) until
SATURDAY,
SEPTEMBER 30
(13.30)

P96 The prognostic value of Rheumatoid Factor and anti-citrullinated protein antibodies (ACPA) IgA subtypes for prediction of therapeutic responses in patients with rheumatoid arthritis. *Daniela Sieghart, Farideh Alasti, Paul Studenic, Thomas Horn, Josef Smolen, Daniel Aletaha, Günter Steiner* (Vienna, Austria)

P97 Anti-RA33 (hnRNP-A2/B1) autoantibodies are associated with the therapeutic response to methotrexate and anti-TNF treatment in patients with rheumatoid arthritis. *Daniela Sieghart, Paul Studenic, Thomas Horn, Josef S. Smolen, Daniel Aletaha, Günter Steiner* (Vienna, Austria)

P98 Rheumatoid arthritis patients with anti-acetylated peptide antibodies (AAPA) show a more favourable response to TNF inhibitor treatment and better disease activity control over time. *Paul Studenic, Stephan Blüml, Holger Bang, Daniela Sieghart, Daniel Aletaha, Josef Smolen, Günter Steiner* (Vienna, Austria)

P99 Anti-DPPX antibody associated encephalitis in a patient with SLE and COVID. *Sebastian Rudolph, Matthias Kouba, Ulrich Sack, Winfried Stöcker, Karsten Conrad* (Chemnitz, Germany)

P100 Multiparametric analysis of connective tissue disease specific autoantibodies using a spot immunoassay (SeraSpot® ANA). *Karsten Conrad, Manuela Rejzek, Martin Aringer, Sebastian Rudolph, Leonore Unger, Kirsten Lüthke, Anett Gräßler, Nadja Röber* (Dresden, Germany)

The modern Center of Regenerative Therapies Dresden (CRTD) is located near to the University hospitals in the district Johannstadt. Address of the symposium venue:

CRTD
Fetscherstrasse 105
01307 Dresden

The modern BioInnovationsZentrumDresden is located in the neighbouring building of the symposium venue (CRTD).

Address of the workshop venue:
BioInnovationsZentrumDresden
Tatzberg 4, 01307 Dresden

September 27: 08.00 - 21.00
September 28: 08.00 - 19.30
September 29: 08.00 - 17.45
September 30: 08.00 - 17.00

+49 160 98 35 87 47 and +49 351 458 82 600

Karsten Conrad, Germany

Luis E.C. Andrade, Brazil
Edward K.L. Chan, USA
Marvin Fritzler, Canada
Ger J. M. Pruijn, The Netherlands
Günter Steiner, Austria

Yehuda Shoenfeld, Israel

Nicola Bizzaro, Italy
Martin Blüthner, Germany
Dimitrios P. Bogdanos, Greece
Xavier Bossuyt, Belgium
Carlos A. Casiano, USA
Elena Csernok, Germany
Jan Damoiseaux, The Netherlands
Manfred Herold, Austria
Michael Mahler, USA
Pier Luigi Meroni, Italy
Carlos Alberto von Mühlen, Brazil
Johan Rönnelid, Sweden
Minoru Satoh, Japan
Joanna Sheldon, UK

Rico Hiemann
Thorsten Krieger
Ulrich Sack
Werner Schößler
Clemens August Schulze Lohoff
Andreas Schwab
(Members of the Advisory Committee of the GFID e.V.)

GENERAL INFORMATION

Symposium Venue

Workshop Venue (September 26, 2017)

Registration office

Phone on site

Chairman

Co-Chairmen

Honorary Chair

International Advisory Board

National Organizing Committee

GENERAL INFORMATION

Language

English, no simultaneous translation

Organization (Registration, Reservation, Exhibition)

Silke Zwjatkow
GFID e.V.
Wasastra_e 14
01219 Dresden, Germany
Phone +49 351 26 32 279
Fax +49 351 26 32 280
e-mail: gfov.ev@me.com

Registration fee (on site)

| | |
|--------------------|---------|
| Participants | EUR 500 |
| GFID members | EUR 480 |
| Students/Residents | EUR 280 |
| One day ticket | EUR 150 |

(includes unlimited access to all scientific sessions, welcome reception, industrial exhibition, one copy of the electronic edition of the conference book and one copy of the book „Autoantibodies in Organ Specific Autoimmune Diseases – A Diagnostic Reference“, 2nd edition.)

Members of the Dresden University and the CRTD are free of charge.

Social programme

Wednesday,
September 27,
2017

18.00

Get together in the Center of Regenerative Therapies Dresden (CRTD)

Friday,
September 29,
2017

17.45

Departure by bus starting from the congress venue

18.15

Champagne Reception in the Dresden Zwinger Palace and visit of the famous Old Masters Picture Gallery (special opening exclusively for the symposium group).

The well sorted art, book and gift shop (with books in a number of languages) of the Gallery is open until 19.30 h.

GENERAL INFORMATION

Short walk (300 m) from the Dresden Zwinger Palace passing Dresden Castle and the Fürstenzug (Procession of Princes) to the banqueting hall. (The Procession of Princes is a large mural of a mounted procession of the rulers of Saxony)


Social Dinner in the banqueting hall of Hilton Hotel Dresden with a surprise - you will meet a prominent artist (no formal dresscode)

Return by bus to the CRTD, InterCity hotel and University Guesthouse (The Steigenberger de Saxe hotel is situated in a walking distance of 150 m).

19.30

20.00

22.00



INDUSTRIAL EXHIBITION 1st floor of CRTD

EXHIBITORS AND SPONSORS

The following companies and foundation participate in the industrial exhibition and/or have made a generous sponsorship (in alphabetical order):

AESKU.Diagnostics GmbH & Co. KG

(Wendelsheim, Germany)
www.aesku.com

AlphaScience GmbH

(Riedstadt, Germany)
www.alphascience.de

Bio-Rad Laboratories, Inc.

(Hercules, USA)
www.bio-rad.com

BioSystems S.A.

(Barcelona, Spain)
www.biosystems.com

BioVendor GmbH

(Kassel, Germany)/TestLine Clinical Diagnostics Ltd.
(Brno, Czech Republic)
www.biovendor.com; www.testlinecd.com

BÜHLMANN Laboratories AG

(Schönenbuch, Switzerland)
www.buhlmannlabs.ch

CellTrend GmbH

(Luckenwalde, Germany)
www.celltrend.de

Diarect AG

(Freiburg, Germany)
www.diarect.com

DLD Diagnostika GmbH

(Hamburg, Germany)
www.dld-diagnostika.de

D-tek s.a.

(Mons, Belgium)
www.d-tek.be

EUROIMMUN AG

(Lübeck, Germany)
www.euroimmun.de

GA Generic Assays GmbH

(Dahlewitz, Germany)
www.genericassays.com

Inova Diagnostics, Inc.

(San Diego, USA)
www.inovadx.com

EXHIBITORS AND SPONSORS

Jeffrey Modell Foundation

(New York, USA)

www.info4pi.org

MEDIPAN GMBH

(Dahlewitz, Germany)

www.medipan.de

ravo Diagnostika GmbH

(Freiburg, Germany)

www.ravo.de

R-Biopharm AG

(Darmstadt, Germany)

www.r-biopharm.com

Theradiag

(Croissy Beaubourg, France)

www.theradiag.com

Thermo Fisher Scientific

(Freiburg, Germany)

www.thermoscientific.com/phadia/de

Viramed Biotech AG

(Planegg, Germany)

www.viramed.de

We thank these companies for helping to make this symposium successful.



15th Anniversary of the Society for the Advancement of Immunodiagnostics

In September of 2002, Dr. Karsten Conrad and colleagues founded the "Society for the Advancement of Immunodiagnostics" (Gesellschaft zur Förderung der Immun-diagnostik - GFID e.V.). Through its work the society wants to contribute to help patients with immunologically caused diseases receive an early diagnosis and adequate treatment - especially through the publication of specialized literature and the organization of scientific meetings and workshops. Highlights are the biennial Dresden Symposia on Autoantibodies.

To be able to continue our non-profit work in the future, we would highly appreciate your support in searching funding and sponsoring opportunities.

www.gfid-ev.de


GFID E.V.

Ostsächsische Sparkasse Dresden

IBAN: DE63 8505 0300 3120 0593 57 BIC (SWIFT): OSDDDE81XXX

QUANTA-Lyser® 3000*

Integrated EIA/IFA Processing



Be productive. Be accurate. Be assured.

A new dimension in processing to increase your lab's productivity.



- QUANTA-Lyser 3000 safeguards reagent and patient traceability to ensure integrity of results
- High throughput processing with 240 sample capacity and 4 independent probes
- Frees up valuable staff time by minimizing interventions
- Eliminates disposable tips for significantly lower operational costs

See how QUANTA-Lyser 3000 can increase productivity while lowering operational costs.

For more information about QUANTA-Lyser 3000 please visit inovadx.com or contact your local sales representative.

* Pending CE Mark and FDA Clearance

www.inovadx.com

San Diego, CA 92131 USA

PH: +1-858-586-9900 US Toll Free: 1-800-545-9495 FAX: +1-858-586-9911

QUANTA-Lyser is a registered trademark of Inova Diagnostics, Inc. © 2017 Inova Diagnostics, Inc. All rights reserved.

690607 September 2017 Rev. 0

**Inova
Diagnostics**
A Werfen Company